Please assess the completion status of the following clinical trial:

Trial Title: Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male patients at least 18 years old with severe or moderately severe hemophilia A (facto VIII concentration less than or equal to 2%).~* Negative test for facto VIII inhibitor.~* If applicable, HIV or hepatitis treatment is stable at the time of enrollment.~* Ability to abstain from use of FVIII products for 72 hours at a time.~Exclusion Criteria:~* History of any positive test result for factor VIII inhibitor.~* Presence of any bleeding disorder in addition to Hemophilia A.~* Body weight less than 50 kg.~* History of alcoholism.~* Treatment with investigational drug or device within 30 days prior to the Screening visit.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequence 1 (Type: EXPERIMENTAL): Subjects randomized to receive Treatment A during Period 1, then Treatment B during Period 2.
- Sequence 2 (Type: EXPERIMENTAL): Subjects randomized to receive Treatment B during Period 1, then Treatment B during Period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).